109
Participants
Start Date
September 23, 2010
Primary Completion Date
July 27, 2016
Study Completion Date
August 9, 2016
bimatoprost 20 µg generation 2
Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
bimatoprost 15 µg generation 2
Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
bimatoprost 10 µg generation 2
Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
bimatoprost 6 µg generation 2
Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
bimatoprost 15 µg generation 1
Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
bimatoprost 10 µg generation 1
Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
bimatoprost 0.03%
One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
Asian Eye Institute, Makati City
Pacific Eye and Laser Institute (PELI), Makati City
Eye Associates, Sydney New South Wales
Melbourne Eye Specialists, Fitzroy
Glaucoma Associates of NY, New York
Ophthalmic Consultants of Long Island, Lynbrook
Rochester Ophthalmological Group PC, Rochester
Scott & Christie and Associates, Cranberry Township
Philadelphia Eye Associates, Philadelphia
Glaucoma Consultants, Baltimore
James D. Branch, MD, Winston-Salem
Cornerstone Eye Care, High Point
Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte
Coastal Research Associates, Roswell
Emory University, The Emory Eye Center, Atlanta
The Eye Associates of Manatee, Bradenton
Fundacion Oftalmologica Del Mediterraneo, Valencia
The Sam Rothberg Glaucoma Center,, Tel Litwinsky
Springfield Clinic, Springfield
Moyes Eye Center, Kansas City
Tel Aviv Sourasky Medical Center, Tel Aviv
Glaucoma Associates of TX, Dallas
Kaplan Medical Center, Rohovot
Staedtisches Klinikum Department of Opthalmology, Karlsruhe
R and R Eye Research, San Antonio
Medical Center Ophthalmology Associates, San Antonio
Keystone Research LTD, Austin
Specialty Eye Care, Parker
Focus Clinical Research, Salt Lake City
Doheny Eye Institute, Los Angeles
Wolstan & Goldberg Eye Associates, Torrance
Sall Research Medical Center, Artesia
Shiley Eye Center, Hamilton Glaucoma Center, University of California, San Diego, La Jolla
Pacific Eye Surgeons, San Luis Obispo
Martel Eye Medical Group, Rancho Cordova
Grutzmacher and Lewis, Inc., Sacramento
Shasta Eye Medical Group, Inc., Redding
Legacy Good Samaritan - Devers Eye Institute, Portland
Wenatchee Valley Medical Center, Wenatchee
Spokane Eye Clinical Research, Spokane
Singapore National Eye Center, Singapore
Tufts Medical Center/New England Eye Center, Boston
Ophthalmic Consultants of Boston, Boston
ActivMed Practices & Research, Methuen
Clinical Eye Research of Boston/ Charles River Eye Associates, Winchester
Northern New Jersey Eye Institute PA, South Orange
UZ Leuven, Campus St. Rafael, Dienst Oogheelkunde
Universidade Federal de São Paulo/Escola Paulista de Medicina/Hospital São Paulo Departamento de Oftalmologia, São Paulo
A.C. S. Crichton Prof. Corp, Calgary
Eye Care Center, Halifax
Anjema Eye Institute, Chatham
Galen Eye Centre, Kingston
Ivey Eye Institute, London
Institut de l'œil des Laurentides, Boisbriand
Clarity Eye Institute, Vaughan
St. Lukes Medical Center-Quezon City, Metro Manila
Valles Oftalmologia Recerca, Hospital General de Catalunya,, Sant Cugat del Vallès
Lead Sponsor
Allergan
INDUSTRY